Business Context and Reporting Period
This Form 8-K is filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata) for the reporting date of September 30, 2010. The filing serves as a Regulation FD disclosure regarding a material corporate event.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory disclosure event rather than financial performance data.
Material Changes and Events
- Regulation FD Disclosure: On September 30, 2010, OncoGenex Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd. issued a joint press release.
- Event Details: The companies announced the initiation of a second Phase 3 clinical trial for the drug Custirsen.
- Target Population: The trial focuses on men with metastatic prostate cancer.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) by reference but does not contain explicit management commentary, financial guidance, or risk factors within the body of the 8-K text. The document notes that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act unless expressly incorporated by reference in other filings.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for specific trial design details and timelines.
- Confirm the current status of the Custirsen Phase 3 trial in subsequent filings, as this 8-K only marks the initiation.
- Review the partnership agreement terms between OncoGenex and Teva Pharmaceutical Industries Ltd. regarding the trial.
- Note the discrepancy between the metadata company name ("ACHIEVE LIFE SCIENCES, INC.") and the registrant name in the filing ("ONCOGENEX PHARMACEUTICALS, INC.").